Results 31 to 40 of about 7,822 (173)

A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant

Frontiers in Immunology, 2020
Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
Andrew G. Diamos, Andrew G. Diamos, Mary D. Pardhe, Mary D. Pardhe, Haiyan Sun, Haiyan Sun, Joseph G. L. Hunter, Joseph G. L. Hunter, Jacquelyn Kilbourne, Jacquelyn Kilbourne, Qiang Chen, Qiang Chen, Hugh S. Mason, Hugh S. Mason   +13 more
doaj   +1 more source

Lung cancer and oncolytic virotherapy——enemy's enemy

Translational Oncology, 2023
Lung cancer is one of the malignant tumors that seriously threaten human health worldwide, while the covid-19 virus has become people's nightmare after the coronavirus pandemic. There are too many similarities between cancer cells and viruses, one of the
Zhang Li, Zhang Feiyue, Li Gaofeng, Liang Haifeng   +3 more
doaj   +1 more source

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report

Frontiers in Oncology, 2018
Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location.
Guna Proboka, Andra Tilgase, Sergejs Isajevs, Sergejs Isajevs, Agnija Rasa, Pēteris Alberts   +5 more
doaj   +1 more source

Current strategies in engaging oncolytic viruses with antitumor immunity

Molecular Therapy: Oncolytics, 2021
Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni, Divya Ravirala, Shaun Xiaoliu Zhang   +2 more
doaj   +1 more source

Tumor treatment with chemo-virotherapy and MEK inhibitor: A mathematical model of Caputo fractional differential operator

Alexandria Engineering Journal, 2023
Mitogen-activated protein kinase (MEK) inhibitors and oncolytic virotherapy are identified as promising cancer therapies that can enhance the efficacy of other cancer treatments.
M. Moksud Alam, S.M.E.K. Chowdhury, J.T. Chowdhury, Mohammad Mahmud Hasan, M.A. Ullah, Shams Forruque Ahmed   +5 more
doaj   +1 more source

Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734

Viruses
NUT carcinoma (NC) is a rare exceptionally aggressive malignancy, defined by NUTM1 gene translocations, most commonly generating a BRD4::NUTM1 fusion that results in a poor prognosis and limited therapeutic options. Oncolytic virotherapy has emerged as a
Fiona D. Nitschke, Julia Beil, Irina Smirnow, Andrea Schenk, Mary E. Carter, Ulrich M. Lauer, Linus D. Kloker   +6 more
doaj   +1 more source

Modeling dynamics of cancer virotherapy with immune response

Advances in Difference Equations, 2020
Virotherapy is a therapeutic treatment for cancer. It uses genetically engineered viruses to selectively infect, replicate in, and destroy cancer cells without damaging normal cells.
Salma M. Al-Tuwairqi, Najwa O. Al-Johani, Eman A. Simbawa   +2 more
doaj   +1 more source

Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors

Viruses
NUT (nuclear-protein-in-testis) carcinoma (NC) is a highly aggressive tumor disease. Given that current treatment regimens offer a median survival of six months only, it is likely that this type of tumor requires an extended multimodal treatment approach
Stavros Sotiriadis, Julia Beil, Susanne Berchtold, Irina Smirnow, Andrea Schenk, Ulrich M. Lauer   +5 more
doaj   +1 more source

Myxoma Virus dsRNA Binding Protein M029  Inhibits the Type I IFN‐Induced Antiviral State in a  Highly Species‐Specific Fashion

Viruses, 2017
Myxoma virus (MYXV) is Leporipoxvirus that possesses a specific rabbit‐restricted host tropism but exhibits a much broader  cellular host range in cultured cells.
Masmudur M. Rahman, Grant McFadden
doaj   +1 more source

Personalizing Oncolytic Virotherapy?

Molecular Therapy, 2007
raditionally, cancer therapies have been based on the empiric discovery of drugs and/or biological agents that act selectively against tumor cells. Recently, however, a generation of rationally discov-ered drugs and agents has been developed that shows encouraging benefi t in treating cancers.
Kaur, Balveen, Chiocca, E Antonio
openaire   +2 more sources